ZVRA vs. TRVI, OMER, OGI, CAPR, GALT, PBYI, IVA, VERU, ATOS, and LFCR
Should you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Trevi Therapeutics (TRVI), Omeros (OMER), Organigram (OGI), Capricor Therapeutics (CAPR), Galectin Therapeutics (GALT), Puma Biotechnology (PBYI), Inventiva (IVA), Veru (VERU), Atossa Therapeutics (ATOS), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical preparations" industry.
Trevi Therapeutics (NASDAQ:TRVI) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment, community ranking and dividends.
Trevi Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 235.97%. Zevra Therapeutics has a consensus target price of $19.50, suggesting a potential upside of 325.76%. Given Trevi Therapeutics' higher possible upside, analysts plainly believe Zevra Therapeutics is more favorable than Trevi Therapeutics.
Trevi Therapeutics received 65 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Zevra Therapeutics an outperform vote while only 60.94% of users gave Trevi Therapeutics an outperform vote.
Trevi Therapeutics has a net margin of 0.00% compared to Trevi Therapeutics' net margin of -181.76%. Zevra Therapeutics' return on equity of -39.54% beat Trevi Therapeutics' return on equity.
In the previous week, Trevi Therapeutics had 5 more articles in the media than Zevra Therapeutics. MarketBeat recorded 8 mentions for Trevi Therapeutics and 3 mentions for Zevra Therapeutics. Trevi Therapeutics' average media sentiment score of 1.30 beat Zevra Therapeutics' score of 1.03 indicating that Zevra Therapeutics is being referred to more favorably in the news media.
95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 24.4% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Trevi Therapeutics has higher earnings, but lower revenue than Zevra Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Trevi Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500.
Summary
Trevi Therapeutics and Zevra Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Zevra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zevra Therapeutics Competitors List
Related Companies and Tools
